東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

A Cross-Sectional Survey of Drug-Res...

Han, Zay Yar.

FindBook

Google Book

Amazon

博客來

A Cross-Sectional Survey of Drug-Resistance Polymorphisms in Plasmodium falciparum K13, Plasmepsin 2 and Pfmdr-1 in Sentinel Sites in Myanmar.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	A Cross-Sectional Survey of Drug-Resistance Polymorphisms in Plasmodium falciparum K13, Plasmepsin 2 and Pfmdr-1 in Sentinel Sites in Myanmar./
作者:	Han, Zay Yar.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2021,
面頁冊數:	56 p.
附註:	Source: Masters Abstracts International, Volume: 82-12.
Contained By:	Masters Abstracts International82-12.
標題:	Health sciences. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28320852
ISBN:	9798738653322

A Cross-Sectional Survey of Drug-Resistance Polymorphisms in Plasmodium falciparum K13, Plasmepsin 2 and Pfmdr-1 in Sentinel Sites in Myanmar.
Han, Zay Yar.

A Cross-Sectional Survey of Drug-Resistance Polymorphisms in Plasmodium falciparum K13, Plasmepsin 2 and Pfmdr-1 in Sentinel Sites in Myanmar. - Ann Arbor : ProQuest Dissertations & Theses, 2021 - 56 p.

Source: Masters Abstracts International, Volume: 82-12.

Thesis (M.S.)--Duke University, 2021.

This item must not be sold to any third party vendors.

Background: Plasmodium falciparum has developed resistance against artemisinin and partner drugs that have been widely used globally as artemisinin-based combination therapies (ACT). Such resistance, poses the greatest challenge to the prospect of malaria elimination in the Greater Mekong Subregion (GMS). Genetic polymorphisms in P. falciparum that confer resistance to the drugs that are part of two most commonly used ACT in the GMS, artemisinin-lumefantrine (AL) and dihydroartemisisnin-piperaquine (DP). Single point mutations in Kelch propeller domain of falciparum chromosome 13 (K13) for artemisinin resistance, and copy number variations of plasmepsin 2/3 are associated with piperaquine resistance, and Pfmdr-1 for mefloquine and lumefantrine resistance. Although the efficacy is high for ACTs in Myanmar, molecular markers of resistance to either of the drugs in ACT can still be present and may indicate that the drugs will be at risk in the near future. Therefore, this study aimed to detect genetic polymorphisms in K13, Pfmdr-1, and plasmepsin 2 (Pfpm-2) that mediate ACT treatment outcomes in Myanmar. Methods: The current study uses a cross-sectional study design and retrospective analysis of laboratory samples collected in previous therapeutic efficacy studies (TES) conducted during 2014 to 2018 in nine sentinel malaria endemic remote townships in Myanmar. The ACTs used in these TES were artemether-lumefantrine, dihydroartemisinin-piperaquine, and pyronaridine-artesunate. 176 samples were randomly selected out of 651 samples from nine TES sites because of the time constraint. K13 genotyping was done by Sanger sequencing, and the copy numbers of Pfpm-2 and Pfmdr-1 were quantified by real-time polymerase chain reaction. Results: Among 176 randomly selected pre-treatment parasites, we observed non- synonymous mutation in the K13 gene in 25% (42/169; 95% CI: 18.3, 31.4). Overall, 23% (39/169; 95% CI: 16.7, 29.4) of infections harbored a K13 mutation that has been validated as associated with artemisinin resistance. Among these, 58.9% (23/39) encoded the F446I substitution. The prevalence of parasites harboring the C580Y mutation that is the most closely associated with artemisinin resistance was 6.5% (11/169; 95% CI: 2.8, 10.2), and was present in 4 out of 9 study sites. Only 1 sample 0.6% (1/172; 95% CI: 0, 1.7) harbored more than one copy of Pfpm-2; this parasite also contained the K13 C580Y mutation conferring artemisinin resistance. No parasites harbored more than one copy of Pfmdr-1. Conclusion: Consistent with the high efficacy of ACTs in Myanmar, there were little evidence of resistance to artemisinin or partner drugs by analysis of molecular markers. However, there was remarkable amount of K13 molecular markers (C580Y, F446I, R561H) seen in this study. These observed K13 markers have already been confirmed and validated by WHO. This finding may be a warning sign of developing artemisinin resistance which may, in turn, have an effect on the malaria elimination process in Myanmar. Emergence of drug resistant malaria in GMS threatens the malaria elimination effort in the region as well as globally. Continued monitoring of artemisinin and its partner drugs resistance is needed to prevent the spread of drug resistant malaria.

ISBN: 9798738653322Subjects--Topical Terms:

3168359
Health sciences.
Subjects--Index Terms:

Drug resistant malaria

A Cross-Sectional Survey of Drug-Resistance Polymorphisms in Plasmodium falciparum K13, Plasmepsin 2 and Pfmdr-1 in Sentinel Sites in Myanmar.
LDR:04684nmm a2200457 4500 001 2281441
005 20210920103004.5
008 220723s2021 ||||||||||||||||| ||eng d
020 $a 9798738653322
035 $a (MiAaPQ)AAI28320852
035 $a AAI28320852
040 $a MiAaPQ $c MiAaPQ
100 1 $a Han, Zay Yar. $3 3560075
245 1 0 $a A Cross-Sectional Survey of Drug-Resistance Polymorphisms in Plasmodium falciparum K13, Plasmepsin 2 and Pfmdr-1 in Sentinel Sites in Myanmar.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2021
300 $a 56 p.
500 $a Source: Masters Abstracts International, Volume: 82-12.
500 $a Advisor: Taylor, Steve M.
502 $a Thesis (M.S.)--Duke University, 2021.
506 $a This item must not be sold to any third party vendors.
520 $a Background: Plasmodium falciparum has developed resistance against artemisinin and partner drugs that have been widely used globally as artemisinin-based combination therapies (ACT). Such resistance, poses the greatest challenge to the prospect of malaria elimination in the Greater Mekong Subregion (GMS). Genetic polymorphisms in P. falciparum that confer resistance to the drugs that are part of two most commonly used ACT in the GMS, artemisinin-lumefantrine (AL) and dihydroartemisisnin-piperaquine (DP). Single point mutations in Kelch propeller domain of falciparum chromosome 13 (K13) for artemisinin resistance, and copy number variations of plasmepsin 2/3 are associated with piperaquine resistance, and Pfmdr-1 for mefloquine and lumefantrine resistance. Although the efficacy is high for ACTs in Myanmar, molecular markers of resistance to either of the drugs in ACT can still be present and may indicate that the drugs will be at risk in the near future. Therefore, this study aimed to detect genetic polymorphisms in K13, Pfmdr-1, and plasmepsin 2 (Pfpm-2) that mediate ACT treatment outcomes in Myanmar. Methods: The current study uses a cross-sectional study design and retrospective analysis of laboratory samples collected in previous therapeutic efficacy studies (TES) conducted during 2014 to 2018 in nine sentinel malaria endemic remote townships in Myanmar. The ACTs used in these TES were artemether-lumefantrine, dihydroartemisinin-piperaquine, and pyronaridine-artesunate. 176 samples were randomly selected out of 651 samples from nine TES sites because of the time constraint. K13 genotyping was done by Sanger sequencing, and the copy numbers of Pfpm-2 and Pfmdr-1 were quantified by real-time polymerase chain reaction. Results: Among 176 randomly selected pre-treatment parasites, we observed non- synonymous mutation in the K13 gene in 25% (42/169; 95% CI: 18.3, 31.4). Overall, 23% (39/169; 95% CI: 16.7, 29.4) of infections harbored a K13 mutation that has been validated as associated with artemisinin resistance. Among these, 58.9% (23/39) encoded the F446I substitution. The prevalence of parasites harboring the C580Y mutation that is the most closely associated with artemisinin resistance was 6.5% (11/169; 95% CI: 2.8, 10.2), and was present in 4 out of 9 study sites. Only 1 sample 0.6% (1/172; 95% CI: 0, 1.7) harbored more than one copy of Pfpm-2; this parasite also contained the K13 C580Y mutation conferring artemisinin resistance. No parasites harbored more than one copy of Pfmdr-1. Conclusion: Consistent with the high efficacy of ACTs in Myanmar, there were little evidence of resistance to artemisinin or partner drugs by analysis of molecular markers. However, there was remarkable amount of K13 molecular markers (C580Y, F446I, R561H) seen in this study. These observed K13 markers have already been confirmed and validated by WHO. This finding may be a warning sign of developing artemisinin resistance which may, in turn, have an effect on the malaria elimination process in Myanmar. Emergence of drug resistant malaria in GMS threatens the malaria elimination effort in the region as well as globally. Continued monitoring of artemisinin and its partner drugs resistance is needed to prevent the spread of drug resistant malaria.
590 $a School code: 0066.
650 4 $a Health sciences. $3 3168359
650 4 $a Medicine. $3 641104
650 4 $a Molecular biology. $3 517296
650 4 $a Epidemiology. $3 568544
650 4 $a Genetics. $3 530508
650 4 $a Public health. $3 534748
650 4 $a Southeast Asian studies. $3 3344898
653 $a Drug resistant malaria
653 $a Artemisinin
653 $a Greater Mekong Subregion
653 $a Piperaquine resistance
653 $a Mefloquine
653 $a Lumefantrine
653 $a Mutations
653 $a Artemisinin-based combination therapies
690 $a 0566
690 $a 0573
690 $a 0222
690 $a 0564
690 $a 0369
690 $a 0766
690 $a 0307
710 2 $a Duke University. $b Global Health. $3 2092989
773 0 $t Masters Abstracts International $g 82-12.
790 $a 0066
791 $a M.S.
792 $a 2021
793 $a English
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28320852